Heterologous prime-boost vaccination

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

Shiver, J. W., Fu, T., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,173

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

Amara, R. R. (2001) · Science · doi:10.1126/science.1058915 · Cited by 1,110

The prime-boost strategy: exciting prospects for improved vaccination

Ramshaw, I. A., & Ramsay, A. J. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01612-1 · Cited by 373

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

Girard, M. P., Kiény, M. P., Pinter, A., Barré‐Sinoussi, F., Nara, P. L., Kolbe, H. V. J., Kusumi, K., Chaput, A., Reinhart, T. A., & Muchmore, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.542 · Cited by 353

Protection of Macaques Against SIV Infection by Subunit Vaccines of SIV Envelope Glycoprotein gp160

Hu, S.-L., Abrams, K., Barber, G. N., Moran, P. A., Zarling, J. M., Langlois, A. J., Kuller, L., Morton, W. R., & Benveniste, R. Ė. (1992) · Science · doi:10.1126/science.1531159 · Cited by 335

Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus

Kent, S. J., Zhao, A., Best, S. J., Chandler, J. D., Boyle, D. B., & Ramshaw, I. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.10180-10188.1998 · Cited by 325

Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen

Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, S. A., Cook, N. M., Smith, G. L., Watkins, D. I., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7524-7532.1999 · Cited by 304

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

Harari, A., Bart, P., Stöhr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O. W., Barber, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071331 · Cited by 299

Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides

Emini, E. A., Jameson, B. A., & Wimmer, E. (1983) · Nature · doi:10.1038/304699a0 · Cited by 237

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS

Zagury, D., Bernard, J., Cheynier, R., Desportes, I., Leonard, R., Fouchard, M., Réveil, B., Ittelé, D., Lurhuma, Z., Mbayo, K., et al. (1988) · Nature · doi:10.1038/332728a0 · Cited by 185

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers

Wang, S., Kennedy, J. S., West, K., Montefiori, D. C., Coley, S., Lawrence, J., Shen, S., Green, S., Rothman, A. L., Ennis, F. A., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.024 · Cited by 180

A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge

Dunachie, S. J., Walther, M. R., Epstein, J., Keating, S. M., Berthoud, T. K., Andrews, L., Andersen, R. F., Bejon, P., Goonetilleke, N. P., Poulton, I. D., et al. (2006) · Infection and Immunity · doi:10.1128/iai.00590-06 · Cited by 164

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

Barnett, S. W. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00264-2 · Cited by 146

Current progress of DNA vaccine studies in humans

Lu, S., Wang, S., & Grimes-Serrano, J. M. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.2.175 · Cited by 143

Safety and Immunogenicity of an HIV Subtype B and E Prime‐Boost Vaccine Combination in HIV‐Negative Thai Adults

Nitayaphan, S., Pitisuttithum, P., Karnasuta, C., Eamsila, C., de Souza, M. S., Morgan, P., Polonis, V. R., Benenson, M. W., VanCott, T., Ratto‐Kim, S., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/422258 · Cited by 139

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

Amara, R. R., Villinger, F. J., Altman, J. D., Lydy, S. L., O’Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G., Wyatt, L. S., et al. (2001) · Science · doi:10.1126/science.292.5514.69 · Cited by 133

Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting

Richmond, J. F. L., Lu, S., Santoro, J. C., Weng, J., Hu, S.-L., Montefiori, D. C., & Robinson, H. L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.9092-9100.1998 · Cited by 124

Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines

Barouch, D. H., McKay, P. F., Sumida, S. M., Santra, S., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Chakrabarti, B. K., Xu, L., Nabel, G. J., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8729-8735.2003 · Cited by 122

Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1

Beddows, S. A., Schülke, N., Kirschner, M. W., Barnes, K., Franti, M., Michael, E., Ketas, T. J., Sanders, R. W., Maddon, P. J., Olson, W. C., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.8812-8827.2005 · Cited by 119

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E

Wang, S., Pal, R., Mascola, J. R., Chou, T.-H. W., Mboudjeka, I., Shen, S., Liu, Q., Whitney, S., Keen, T., Nair, B. C., et al. (2006) · Virology · doi:10.1016/j.virol.2006.02.032 · Cited by 110

In vivo Effects of Vaccination with Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer

García-Hernández, M. D. L. L., Gray, A., Hubby, B., & Kast, W. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2996 · Cited by 105

Enhanced Immunogenicity of gp120 Protein When Combined with Recombinant DNA Priming To Generate Antibodies That Neutralize the JR-FL Primary Isolate of Human Immunodeficiency Virus Type 1

Wang, S., Arthos, J. A., Lawrence, J. M., Ryk, D. V., Mboudjeka, I., Shen, S., Chou, T.-H. W., Montefiori, D. C., & Lu, S. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7933-7937.2005 · Cited by 103

rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector

Magalhaes, I., Sizemore, D. R., Ahmed, R. K. S., Mueller, S., Wehlin, L., Scanga, C. A., Weichold, F., Schirru, G., Pau, M. G., Goudsmit, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003790 · Cited by 95

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

Pal, R., Wang, S., Kalyanaraman, V. S., Nair, B. C., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N., Mboudjeka, I., et al. (2006) · Virology · doi:10.1016/j.virol.2005.12.029 · Cited by 94

Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

Wang, S., Parker, C., Taaffe, J. E., Solórzano, A., García‐Sastre, A., & Lu, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.073 · Cited by 91

Improved Induction of Antibodies against Key Neutralizing Epitopes by Human Immunodeficiency Virus Type 1 gp120 DNA Prime-Protein Boost Vaccination Compared to gp120 Protein-Only Vaccination

Vaine, M., Wang, S., Crooks, E. T., Jiang, P., Montefiori, D. C., Binley, J. Μ., & Lu, S. (2008) · Journal of Virology · doi:10.1128/jvi.00562-08 · Cited by 79

Priming with Plasmid DNAs Expressing Interleukin-12 and Simian Immunodeficiency Virus Gag Enhances the Immunogenicity and Efficacy of an Experimental AIDS Vaccine Based on Recombinant Vesicular Stomatitis Virus

Egan, M. A., Chong, S. Y., Megati, S., Montefiori, D. C., Rose, N. F., Boyer, J., Sidhu, M. K., Quiroz, J., Rosati, M., Schadeck, E. B., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.629 · Cited by 73

Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins

Otten, G. R., Schaefer, M. E., Doe, B., Liu, H., Srivastava, I. K., Megede, J. Z., Kazzaz, J., Lian, Y., Singh, M., Ugozzoli, M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8189-8200.2005 · Cited by 72

DNA Priming-Protein Boosting Enhances Both Antigen-Specific Antibody and Th1-Type Cellular Immune Responses in a Murine Herpes Simplex Virus-2 gD Vaccine Model

Sin, J.-I., Bagarazzi, M. L., Pachuk, C. J., & Weiner, D. B. (1999) · DNA and Cell Biology · doi:10.1089/104454999314917 · Cited by 70

Multifunctional T-Cell Characteristics Induced by a Polyvalent DNA Prime/Protein Boost Human Immunodeficiency Virus Type 1 Vaccine Regimen Given to Healthy Adults Are Dependent on the Route and Dose of Administration

Bansal, A., Jackson, B., West, K., Wang, S., Lu, S., Kennedy, J. S., & Goepfert, P. (2008) · Journal of Virology · doi:10.1128/jvi.00068-08 · Cited by 70

The prime-boost concept applied to HIV preventive vaccines.

Jl, E., & Plotkin, S. A. (1997) · PubMed · Cited by 67

Neutralizing Antibodies Against HIV-1 BRU and SF2 Isolates Generated in Mice Immunized with Recombinant Vaccinia Virus Expressing HIV-1 (BRU) Envelope Glycoproteins and Boosted with Homologous gp160

Hu, S., KLANIECKI, J., Dykers, T., Sridhar, P., & Travis, B. M. (1991) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1991.7.615 · Cited by 64

The Order of Prime-Boost Vaccination of Neonatal Calves with Mycobacterium bovis BCG and a DNA Vaccine Encoding Mycobacterial Proteins Hsp65, Hsp70, and Apa Is Not Critical for Enhancing Protection against Bovine Tuberculosis

Skinner, M. A., Wedlock, D. N., de Lisle, G. W., Cooke, M. M., Tascon, R. E., Ferraz, J. C., Lowrie, D. B., Vordermeier, H. M., Hewinson, R. G., & Buddle, B. M. (2005) · Infection and Immunity · doi:10.1128/iai.73.7.4441-4444.2005 · Cited by 64

Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting

Wang, Q., Sun, S., Zhenlin, H., Yin, M., Xiao, C.-J., & Zhang, J. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.029 · Cited by 58

Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime–adenovirus boost

Park, S., Yang, S.-H., Lee, C. G., Youn, J., Chang, J., & Sung, Y. C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00499-7 · Cited by 46

Combination DNA plus protein HIV vaccines

Lu, S. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0028-1 · Cited by 45

A Combined DNA Vaccine-Prime, BCG-Boost Strategy Results in Better Protection Against Mycobacterium bovis Challenge

Cai, H., Yu, D.-H., Hu, X.-D., Li, S. X., & Zhu, Y. (2006) · DNA and Cell Biology · doi:10.1089/dna.2006.25.438 · Cited by 40

Preexposure Efficacy of a Novel Combination DNA and Inactivated Rabies Virus Vaccine

Biswas, S., Reddy, G. S., Srinivasan, V. A., & Rangarajan, P. N. (2001) · Human Gene Therapy · doi:10.1089/104303401753153965 · Cited by 36

Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting

He, X., Sun, S., Zhenlin, H., Jun, L., Jiang, L., Feng-juan, Z., Ya-nan, Z., & Ying-Jun, G. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.10.013 · Cited by 30

Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization

Herrmann, J. E., Wang, S., Zhang, C., Panchal, R. G., Bavari, S., Lyons, C. R., Lovchik, J. A., Golding, B., Shiloach, J., & Lu, S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.065 · Cited by 29

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines

Fernandes, Q., Inchakalody, V. P., Merhi, M., Mestiri, S., Taib, N., El-Ella, D. M. A., Bedhiafi, T., Raza, A., Al-Zaidan, L., Mohsen, M. O., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2031274 · Cited by 466

Sputnik V COVID-19 vaccine candidate appears safe and effective

Jones, I. M., & Roy, P. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00191-4 · Cited by 378

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development

Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. A. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00120 · Cited by 348

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Hillus, D., Schwarz, T., Tober‐Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00357-x · Cited by 336

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

Mendonça, S. A., Lőrincz, R., Rice-Boucher, P. J., & Curiel, D. T. (2021) · npj Vaccines · doi:10.1038/s41541-021-00356-x · Cited by 313

Streptococcus pneumoniae’s Virulence and Host Immunity: Aging, Diagnostics, and Prevention

Brooks, L. R. K., & Mias, G. I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01366 · Cited by 309

Pre-existing immunity against Ad vectors

Fausther‐Bovendo, H., & Kobinger, G. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29594 · Cited by 285

Effect of vaccine administration modality on immunogenicity and efficacy

Zhang, L., Wang, W., & Wang, S. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1081067 · Cited by 256

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

Kardani, K., Bolhassani, A., & Shahbazi, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.062 · Cited by 262

HIV infection

Bekker, L., Beyrer, C., Mgodi, N. M., Lewin, S. R., Delany‐Moretlwe, S., Taiwo, B., Masters, M. C., & Lazarus, J. V. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00452-3 · Cited by 289

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

Rotshild, V., Raccah, B. H., Miskin, I. N., Muszkat, M., & Matok, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-02321-z · Cited by 232

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 225

Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination

Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J., Massardier-Pilonchery, A., et al. (2021) · Nature · doi:10.1038/s41586-021-04120-y · Cited by 213

The status of tuberculosis vaccine development

Schrager, L. K., Vekemens, J., Drager, N., Lewinsohn, D. M., & Olesen, O. F. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30625-5 · Cited by 196

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

He, Q., Mao, Q., An, C., Zhang, J., Gao, F., Bian, L., Li, C., Liang, Z., Xu, M., & Wang, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1902245 · Cited by 152

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Li, J., Hou, L., Guo, X., Jin, P., Wu, S., Zhu, J., Pan, H., Wang, X., Song, Z., Wan, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01677-z · Cited by 154

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review

Girard, M. P., Osmanov, S., Assossou, O. M., & Kiény, M.-P. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.085 · Cited by 139

Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases

Pan, T., Zhu, J., Mahalingam, M., Batra, H., & Rao, V. B. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.025 · Cited by 128

Therapeutic HPV vaccines

Hancock, G., Hellner, K., & Dorrell, L. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.09.008 · Cited by 123

New viral vectors for infectious diseases and cancer

Sasso, E., D’Alise, A. M., Zambrano, N., Scarselli, E., Folgori, A., & Nicosia, A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101430 · Cited by 120

COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts

Rashedi, R., Samieefar, N., Masoumi, N., Mohseni, S., & Rezaei, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27463 · Cited by 118

An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times

Montero, C. G., Fraile‐Μartinez, O., Bravo, C., Torres‐Carranza, D., Sánchez‐Trujillo, L., Gomez-Lahoz, A. M., Guijarro, L. G., García‐Honduvilla, N., Asúnsolo, Á., Buján, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050433 · Cited by 112

Dengue vaccines: recent developments, ongoing challenges and current candidates

McArthur, M. A., Sztein, M. B., & Edelman, R. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.815412 · Cited by 108

Advances in structure-based vaccine design

Kulp, D. W., & Schief, W. R. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.05.010 · Cited by 102

Progress in HIV vaccine development

Hsu, D. C., & O’Connell, R. J. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1276138 · Cited by 109

Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field

Majhen, D., Calderón, H., Chandra, N., Fajardo, C. A., Rajan, A., Alemany, R., & Custers, J. H. H. V. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.235 · Cited by 102

Oncolytic Viruses: Therapeutics With an Identity Crisis

Breitbach, C. J., Lichty, B. D., & Bell, J. C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.06.046 · Cited by 102

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity

Vaine, M., Wang, S., Hackett, A., Arthos, J. A., & Lu, S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.02.006 · Cited by 100

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine

Zhang, J., He, Q., An, C., Mao, Q., Gao, F., Bian, L., Xing, W., Wang, Q., Liu, P., Song, L., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1957401 · Cited by 95

Adjuvants in the Driver’s Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators

Bergmann‐Leitner, E. S., & Leitner, W. W. (2014) · Vaccines · doi:10.3390/vaccines2020252 · Cited by 101

Immunotherapy of cancers comes of age

Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 97

Heterologous prime–boost strategies for COVID-19 vaccines

Sapkota, B., Saud, B., Shrestha, R., Al-Fahad, D., Sah, R., Shrestha, S., & Rodriguez-Morales, A. J. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab191 · Cited by 92

DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy

Tiptiri-Kourpeti, A., Spyridopoulou, K., Pappa, A., & Chlichlia, K. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.05.004 · Cited by 94

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

Ockenhouse, C. F., Regules, J. A., Tosh, D., Cowden, J., Kathcart, A. K., Cummings, J. F., Paolino, K. M., Moon, J. E., Komisar, J. L., Kamau, E. T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131571 · Cited by 92

Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases

Grunwald, T., & Ulbert, S. (2015) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2015.4.1.1 · Cited by 93

A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines

Suschak, J. J., Wang, S., Fitzgerald, K. A., & Lu, S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501836 · Cited by 87

Live bacterial vaccine vectors: An overview

da Silva, A. J., Zangirolami, T. C., Novo‐Mansur, M. T. M., Giordano, R. C., & Martins, E. A. L. (2014) · Brazilian Journal of Microbiology · doi:10.1590/s1517-83822014000400001 · Cited by 92

Current State of the First COVID-19 Vaccines

Prüβ, B. M. (2021) · Vaccines · doi:10.3390/vaccines9010030 · Cited by 90

Urgency and necessity of Epstein-Barr virus prophylactic vaccines

Zhong, L., Krummenacher, C., Zhang, W., Hong, J., Feng, Q., Chen, Y., Zhao, Q., Zeng, M., Zeng, Y., Xu, M., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00587-6 · Cited by 88

Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch

Kim, Y., Song, J.-M., Lipatov, A. S., Choi, S., Lee, J. W., Donis, R. O., Compans, R. W., Kang, S., & Prausnitz, M. R. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.03.010 · Cited by 82

DNA and mRNA vaccination against allergies

Scheiblhofer, S., Thalhamer, J., & Weiss, R. (2018) · Pediatric Allergy and Immunology · doi:10.1111/pai.12964 · Cited by 80

Plague vaccine: recent progress and prospects

Sun, W., & Singh, A. K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0105-9 · Cited by 83

Rhoptry antigens as Toxoplasma gondii vaccine target

Foroutan, M., Ghaffarifar, F., Sharifi, Z., Dalimi, A., & Jorjani, O. (2019) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2019.8.1.4 · Cited by 76

Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine

Cai, H., Shukla, S., Wang, C., Hema, M., & Steinmetz, N. F. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b01523 · Cited by 76

Potency, Efficacy and Durability of DNA/DNA, DNA/Protein and Protein/Protein Based Vaccination Using gp63 Against Leishmania donovani in BALB/c Mice

Mazumder, S., Maji, M., Das, A., & Ali, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014644 · Cited by 76

DNA Vaccination in the Skin Using Microneedles Improves Protection Against Influenza

Song, J.-M., Kim, Y., Eunju, O., Compans, R. W., Prausnitz, M. R., & Kang, S. (2012) · Molecular Therapy · doi:10.1038/mt.2012.69 · Cited by 76

Single-injecting, bioinspired nanocomposite hydrogel that can recruit host immune cells in situ to elicit potent and long-lasting humoral immune responses

Korupalli, C., Pan, W., Yeh, C.-Y., Chen, P.-M., Mi, F., Tsai, H.-W., Chang, Y., Wei, H.-J., & Sung, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119268 · Cited by 75

A critical evaluation of a nicotine vaccine within a self-administration behavioral model

Moreno, A. Y., Azar, M. R., Warren, N. A., Dickerson, T. J., Koob, G. F., & Janda, K. D. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900213u · Cited by 73

Development of Vaccines Against Burkholderia Pseudomallei

Patel, N., Conejero, L., de Reynal, M., Easton, A., Bancroft, G. J., & Titball, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00198 · Cited by 73

Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies

Oladejo, M., Paterson, Y. Y. W., & Wood, L. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642316 · Cited by 74

Prime-Boost Immunization Strategies against Chikungunya Virus

Hallengärd, D., Lum, F., Kümmerer, B. M., Lulla, A., Lulla, V., García‐Arriaza, J., Fazakerley, J. K., Roques, P., Grand, R. L., Merits, A., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01926-14 · Cited by 72

Vaccination against the Epstein–Barr virus

Rühl, J., Leung, C. S. K., & Münz, C. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03538-3 · Cited by 71

Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines

Carstens, M. G., Camps, M. G. M., Henriksen‐Lacey, M., Franken, K. L. M. C., Ottenhoff, T. H. M., Perrie, Y., Bouwstra, J. A., OSSENDORP, F. A., & Jiskoot, W. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.081 · Cited by 73

Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform

Pérez, O., Romeu, B., Cabrera, O., González, E., Batista-Duharte, A., Labrada, A., Pérez-Nicado, R., Reyes, L. M., González, W. R., Sifontes, S., et al. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00407 · Cited by 71

Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques

Darrah, P. A., DiFazio, R. M., Maiello, P. A., Gideon, H. P., Myers, A. J., Rodgers, M., Hackney, J. A., Lindenstrøm, T., Evans, T. G., Scanga, C. A., et al. (2019) · npj Vaccines · doi:10.1038/s41541-019-0113-9 · Cited by 70

Genetic cancer vaccines: current status and perspectives

Aurisicchio, L., & Ciliberto, G. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.689279 · Cited by 71

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks

Shukarev, G., Callendret, B., Lühn, K., Douoguih, M., & the EBOVAC1 consortium (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1264755 · Cited by 63

Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNA

Zolla‐Pazner, S., Kong, X., Jiang, X., Cardozo, T. J., Nadas, A. J., Cohen, S., Totrov, M. M., Seaman, M. S., Wang, S., & Lu, S. (2011) · Journal of Virology · doi:10.1128/jvi.05086-11 · Cited by 62

TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia)

Jayakumar, A., Castilho, T. M., Park, E., Goldsmith‐Pestana, K., Blackwell, J. M., & McMahon‐Pratt, D. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001204 · Cited by 62

Prime-Boost Strategies in Mucosal Immunization Affect Local IgA Production and the Type of Th Response

Fiorino, F., Pettini, E., Pozzi, G., Medaglini, D., & Ciabattini, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00128 · Cited by 62

Cocktail Anti-Tick Vaccines: The Unforeseen Constraints and Approaches toward Enhanced Efficacies

Ndawula, C., & Tabor, A. E. (2020) · Vaccines · doi:10.3390/vaccines8030457 · Cited by 61

Potentiating Effects of MPL on DSPC Bearing Cationic Liposomes Promote Recombinant GP63 Vaccine Efficacy: High Immunogenicity and Protection

Mazumder, S., Maji, M., & Ali, N. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001429 · Cited by 59

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

Bosaeed, M., Balkhy, H. H., Almaziad, S., Aljami, H. A., Alhatmi, H., Alanazi, H., Alahmadi, M., Jawhary, A., Alenazi, M. W., Almasoud, A., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00193-2 · Cited by 59

Neutralizing Antibody-Independent SARS-CoV-2 Control Correlated with Intranasal Vaccine-Induced CD8 + T-Cell Responses

Ishii, H., Nomura, T., Yamamoto, H., Nishizawa, M., Hau, T. T. T., Harada, S., Seki, S., Nakamura‐Hoshi, M., Okazaki, M., Daigen, S., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100520 · Cited by 57

Polyinosinic-Polycytidylic Acid Is the Most Effective TLR Adjuvant for SIV Gag Protein–Induced T Cell Responses In Nonhuman Primates

Park, H., Adamson, L., Ha, T., Mullen, K., Hagen, S. I., Nogueron, A., Sylwester, A. W., Axthelm, M. K., Legasse, A., Piatak, M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202958 · Cited by 58

Current Advances in Sustained Release Microneedles

Du, G., & Sun, X. (2020) · Pharmaceutical Fronts · doi:10.1055/s-0040-1701435 · Cited by 61

Potency and efficacy of VP20-based vaccine against tilapia lake virus using different prime-boost vaccination regimens in tilapia

Zeng, W., Wang, Y., Chen, X., Wang, Q., Bergmann, S. M., Yang, Y., Wang, Y., Li, B., Lv, Y., Li, H., et al. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.736654 · Cited by 58

How well do vaccines for Bordetella bronchiseptica work in dogs? A critical review of the literature 1977–2014

Ellis, J. A. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.02.006 · Cited by 56

Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles

Kim, Y., Yoo, D., Compans, R. W., Kang, S., & Prausnitz, M. R. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.016 · Cited by 57

Vaccine design based on 16 epitopes of SARS‐CoV‐2 spike protein

He, J., Fan, H., Zhang, J., Chen, Q., Zheng, Z., Zhou, Q., Chen, D., Li, J., & Chen, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26596 · Cited by 53

Duration of immunity to experimental infection with bovine respiratory syncytial virus following intranasal vaccination of young passively immune calves

Ellis, J. A., Gow, S., Mahan, S. M., & Leyh, R. D. (2013) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.243.11.1602 · Cited by 55

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference

Ross, A. L., Bråve, A., Scarlatti, G., Manrique, A., & Buonaguro, L. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70069-4 · Cited by 60

Heterologous Plasmid DNA Prime-Recombinant Human Adenovirus 5 Boost Vaccination Generates a Stable Pool of Protective Long-Lived CD8 + T Effector Memory Cells Specific for a Human Parasite, Trypanosoma cruzi

Rigato, P. O., de Alencar, B. C., Vasconcelos, J. R., Dominguez, M. R., Araújo, A. F., Machado, A. V., Gazzinelli, R. T., Bruña–Romero, O., & Rodrigues, M. M. (2011) · Infection and Immunity · doi:10.1128/iai.01190-10 · Cited by 55

A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines

Zhu, W. S., Pewin, W. P., Wang, C., Luo, Y., Gonzalez, G. X., Mohan, T., Prausnitz, M. R., & Wang, B. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.017 · Cited by 55

Novel prime-boost vaccine strategies against HIV-1

Excler, J., & Kim, J. H. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1640117 · Cited by 54

Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells

Park, H.-Y., Tan, P. S., Kavishna, R., Ker, A., Lu, J., Chan, C. E. Z., Hanson, B. J., MacAry, P. A., Caminschi, I., Shortman, K., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0033-5 · Cited by 51

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021

(2022) · doi:10.1186/s12916-022-02480-4 · Cited by 43

A Human Multi-Epitope Recombinant Vaccinia Virus as a Universal T Cell Vaccine Candidate against Influenza Virus

Goodman, A. G., Heinen, P. P., Guerra, S., Vijayan, A., Sorzano, C. Ó. S., Gómez, C. E., & Estéban, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025938 · Cited by 49

DNA immunization as a technology platform for monoclonal antibody induction

Liu, S., Wang, S., & Lu, S. (2016) · Emerging Microbes & Infections · doi:10.1038/emi.2016.27 · Cited by 49

Recent progress in microneme-based vaccines development againstToxoplasma gondii

Foroutan, M., Zaki, L., & Ghaffarifar, F. (2018) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2018.7.2.93 · Cited by 49

A Full-Length Plasmodium falciparum Recombinant Circumsporozoite Protein Expressed by Pseudomonas fluorescens Platform as a Malaria Vaccine Candidate

Noe, A. R., Espinosa, D. A., Li, X., Coelho-dos-Reis, J. G. A., Funakoshi, R., Giardina, S. L., Jin, H., Retallack, D. M., Haverstock, R., Allen, J. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107764 · Cited by 48

Distribution of Primed T Cells and Antigen-Loaded Antigen Presenting Cells Following Intranasal Immunization in Mice

Ciabattini, A., Pettini, E., Fiorino, F., Prota, G., Pozzi, G., & Medaglini, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019346 · Cited by 48

Targeting the Genital Tract Mucosa with a Lipopeptide/Recombinant Adenovirus Prime/Boost Vaccine Induces Potent and Long-Lasting CD8+ T Cell Immunity against Herpes: Importance of MyD88

Zhang, X., Dervillez, X., Chentoufi, A. A., Badakhshan, T., Bettahi, I., & BenMohamed, L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201121 · Cited by 47

Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C)

Wick, D. A., Martin, S. D., Nelson, B. H., & Webb, J. R. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.11.036 · Cited by 47

Recent advances and hurdles in melanoma immunotherapy

Jandus, C., Speiser, D. E., & Romero, P. J. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00634.x · Cited by 47

The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients

Pollack, S. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1419068 · Cited by 47

Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy

Wang, J., Wang, S., Ye, T., Li, F., Gao, X., Wang, Y., Ye, P., Qing, S., Wang, C., Yue, H., et al. (2020) · Advanced Science · doi:10.1002/advs.202001108 · Cited by 47

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

Brown, S. A., Surman, S. L., Sealy, R. E., Jones, B. G., Slobod, K. S., Branum, K. C., Lockey, T. D., Howlett, N., Freiden, P. J., Flynn, P. M., et al. (2010) · Viruses · doi:10.3390/v2020435 · Cited by 47

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques

Li, Y., Bi, Y., Xiao, H., Yao, Y., Liu, X., Hu, Z., Duan, J., Yang, Y., Li, Z., Li, Y., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1887767 · Cited by 43

Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review

Garg, I., Sheikh, A. B., Pal, S., & Shekhar, R. (2022) · Infectious Disease Reports · doi:10.3390/idr14040057 · Cited by 44

The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination

Hollister, K., Chen, Y., Wang, S., Wu, H., Mondal, A., Clegg, N., Lu, S., & Dent, A. L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28659 · Cited by 44

Ebolavirus vaccines for humans and apes

Fausther‐Bovendo, H., Mulangu, S., & Sullivan, N. J. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.04.003 · Cited by 43

The Coronavirus pandemic – 2022: Viruses, variants & vaccines

Alexandridi, M., Mazej, J., Palermo, E., & Hiscott, J. B. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.02.002 · Cited by 44

Therapeutic Vaccination for HPV-Mediated Cancers

Yan, F., Cowell, L. G., Tomkies, A., & Day, A. T. (2023) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-023-00443-8 · Cited by 43

A DNA vaccine encoding the E protein of West Nile Virus is protective and can be boosted by recombinant domain DIII

Schneeweiß, A., Chabierski, S., Salomo, M., Delaroque, N., Al‐Robaiy, S., Grünwald, T., Bürki, K., Liebert, U. G., & Ulbert, S. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.116 · Cited by 43

A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells

Çuburu, N., Kim, R., Guittard, G. C., Thompson, C. D., Day, P. M., Hamm, D. E., Pang, Y.-Y. S., Graham, B. S., Lowy, D. R., & Schiller, J. T. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800219 · Cited by 45

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation

Pasin, C., Balelli, I., Effelterre, T. P. V., Bockstal, V., Solforosi, L., Prague, M., Douoguih, M., & Thiébaut, R. (2019) · Journal of Virology · doi:10.1128/jvi.00579-19 · Cited by 42

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant

Khong, K.-W., Liu, D., Leung, K., Lu, L., Lam, H., Chen, L., Chan, P.-C., Lam, H.-M., Xie, X., Zhang, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10020160 · Cited by 39

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

Kardani, K., Bolhassani, A., & Shahbazi, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.062 · Cited by 262

Heterologous prime boost COVID 19 vaccination

Launay, O., & Thill, P. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.09.011 · Cited by 6

Heterologous Prime-Boost Vaccination in Tumor Immunotherapy

Palmowski, M. J., & Smith, C. S. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-680-5_9 · Cited by 2

Vaccination strategies, the Power of the Unmatched Double Hits

Al‐Qaisi, T. S., & Abumsimir, B. (2023) · Future Science OA · doi:10.2144/fsoa-2023-0090 · Cited by 3

Safety and Immunogenicity of Heterologous Prime-Boost Vaccinations across different Infectious Diseases: A Scoping Review ProtocolPreprint

Tina, L. O. (2026) · OSF Preprints (OSF Preprints) · doi:10.17605/osf.io/7jtme